Annual ROE
-214.40%
-141.46%-193.94%
December 31, 2023
Summary
- As of February 12, 2025, CYCC annual return on equity is -214.40%, with the most recent change of -141.46% (-193.94%) on December 31, 2023.
- During the last 3 years, CYCC annual ROE has fallen by -176.83% (-470.67%).
- CYCC annual ROE is now -498.44% below its all-time high of 53.81%, reached on December 31, 2001.
Performance
CYCC ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly ROE
-2462.60%
-1805.81%-274.94%
September 30, 2024
Summary
- As of February 12, 2025, CYCC quarterly return on equity is -2462.60%, with the most recent change of -1805.81% (-274.94%) on September 30, 2024.
- Over the past year, CYCC quarterly ROE has dropped by -2235.27% (-983.27%).
- CYCC quarterly ROE is now -1081.51% below its all-time high of 250.90%, reached on March 31, 2004.
Performance
CYCC Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
ROE Formula
ROE = Net Income
Shareholders Equity ✕ 100%
Shareholders Equity ✕ 100%
CYCC ROE Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -193.9% | -983.3% |
| 3 y3 years | -470.7% | -2594.6% |
| 5 y5 years | -444.9% | -2594.6% |
CYCC ROE Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -312.1% | at low | -5332.6% | at low |
| 5 y | 5-year | -470.7% | at low | -6466.9% | at low |
| alltime | all time | -498.4% | at low | -1081.5% | at low |
Cyclacel Pharmaceuticals ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | -2462.60%(+274.9%) |
| Jun 2024 | - | -656.79%(+79.9%) |
| Mar 2024 | - | -365.17%(+60.6%) |
| Dec 2023 | -214.40%(+193.9%) | -227.33%(+39.1%) |
| Sep 2023 | - | -163.46%(+39.6%) |
| Jun 2023 | - | -117.11%(+28.1%) |
| Mar 2023 | - | -91.39%(+27.9%) |
| Dec 2022 | -72.94%(+40.2%) | -71.47%(+29.8%) |
| Sep 2022 | - | -55.08%(+10.5%) |
| Jun 2022 | - | -49.85%(+6.4%) |
| Mar 2022 | - | -46.84%(+3.3%) |
| Dec 2021 | -52.03%(+38.5%) | -45.33%(+5.2%) |
| Sep 2021 | - | -43.07%(+10.7%) |
| Jun 2021 | - | -38.92%(+3.8%) |
| Mar 2021 | - | -37.50%(-5.5%) |
| Dec 2020 | -37.57%(-35.3%) | -39.70%(-13.1%) |
| Sep 2020 | - | -45.70%(-5.8%) |
| Jun 2020 | - | -48.51%(-6.8%) |
| Mar 2020 | - | -52.07%(-1.5%) |
| Dec 2019 | -58.07%(+47.6%) | -52.84%(+10.7%) |
| Sep 2019 | - | -47.74%(+3.7%) |
| Jun 2019 | - | -46.02%(+4.6%) |
| Mar 2019 | - | -43.98%(+11.9%) |
| Dec 2018 | -39.35%(-5.1%) | -39.32%(+11.1%) |
| Sep 2018 | - | -35.40%(-2.0%) |
| Jun 2018 | - | -36.13%(-10.4%) |
| Mar 2018 | - | -40.32%(-9.4%) |
| Dec 2017 | -41.46%(-41.8%) | -44.49%(-16.6%) |
| Sep 2017 | - | -53.32%(-23.0%) |
| Jun 2017 | - | -69.21%(-1.8%) |
| Mar 2017 | - | -70.49%(-5.4%) |
| Dec 2016 | -71.23%(+0.6%) | -74.52%(+4.5%) |
| Sep 2016 | - | -71.30%(+10.4%) |
| Jun 2016 | - | -64.58%(+11.3%) |
| Mar 2016 | - | -58.02%(-8.4%) |
| Dec 2015 | -70.78%(-9.3%) | -63.32%(-4.4%) |
| Sep 2015 | - | -66.21%(-6.4%) |
| Jun 2015 | - | -70.70%(-6.9%) |
| Mar 2015 | - | -75.94%(+1.0%) |
| Dec 2014 | -78.00%(+46.1%) | -75.19%(+12.9%) |
| Sep 2014 | - | -66.60%(+4.1%) |
| Jun 2014 | - | -64.00%(+32.0%) |
| Mar 2014 | - | -48.47%(+3.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2013 | -53.38%(-40.3%) | -46.91%(-22.8%) |
| Sep 2013 | - | -60.79%(+17.2%) |
| Jun 2013 | - | -51.87%(-47.7%) |
| Mar 2013 | - | -99.24%(+14.9%) |
| Dec 2012 | -89.34%(+30.2%) | -86.36%(+27.7%) |
| Sep 2012 | - | -67.61%(-8.0%) |
| Jun 2012 | - | -73.50%(+5.9%) |
| Mar 2012 | - | -69.38%(-4.9%) |
| Dec 2011 | -68.63%(-34.0%) | -72.95%(-3.7%) |
| Sep 2011 | - | -75.75%(-11.3%) |
| Jun 2011 | - | -85.38%(-1.8%) |
| Mar 2011 | - | -86.93%(-19.0%) |
| Dec 2010 | -104.05%(-29.5%) | -107.33%(-28.0%) |
| Sep 2010 | - | -149.04%(-3.4%) |
| Jun 2010 | - | -154.29%(-14.2%) |
| Mar 2010 | - | -179.86%(+6.5%) |
| Dec 2009 | -147.62%(+43.7%) | -168.96%(+19.3%) |
| Sep 2009 | - | -141.64%(-11.9%) |
| Jun 2009 | - | -160.73%(+32.0%) |
| Mar 2009 | - | -121.76%(+22.8%) |
| Dec 2008 | -102.75%(+139.0%) | -99.12%(+13.9%) |
| Sep 2008 | - | -87.02%(+68.9%) |
| Jun 2008 | - | -51.51%(+32.7%) |
| Mar 2008 | - | -38.81%(+6.3%) |
| Dec 2007 | -42.99%(-57.4%) | -36.51%(+32.5%) |
| Sep 2007 | - | -27.56%(-7.5%) |
| Jun 2007 | - | -29.79%(-27.1%) |
| Mar 2007 | - | -40.85%(-42.2%) |
| Dec 2006 | -100.82%(+34.7%) | -70.67%(-14.6%) |
| Sep 2006 | - | -82.79%(-8.4%) |
| Jun 2006 | - | -90.42%(-12.5%) |
| Mar 2006 | - | -103.34%(+54.5%) |
| Dec 2005 | -74.83%(-16.6%) | -66.90%(-3.2%) |
| Sep 2005 | - | -69.13%(-7.0%) |
| Jun 2005 | - | -74.33%(+0.2%) |
| Mar 2005 | - | -74.21%(-70.8%) |
| Dec 2004 | -89.73%(-415.2%) | -254.17%(-41.2%) |
| Sep 2004 | - | -432.43%(-70.5%) |
| Jun 2004 | - | -1468.27%(-685.2%) |
| Mar 2004 | - | 250.90%(+781.3%) |
| Dec 2003 | 28.47%(-29.6%) | 28.47% |
| Dec 2002 | 40.42%(-24.9%) | - |
| Dec 2001 | 53.81%(+5.6%) | - |
| Dec 2000 | 50.98% | - |
FAQ
- What is Cyclacel Pharmaceuticals annual return on equity?
- What is the all time high annual ROE for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals annual ROE year-on-year change?
- What is Cyclacel Pharmaceuticals quarterly return on equity?
- What is the all time high quarterly ROE for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals quarterly ROE year-on-year change?
What is Cyclacel Pharmaceuticals annual return on equity?
The current annual ROE of CYCC is -214.40%
What is the all time high annual ROE for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high annual return on equity is 53.81%
What is Cyclacel Pharmaceuticals annual ROE year-on-year change?
Over the past year, CYCC annual return on equity has changed by -141.46% (-193.94%)
What is Cyclacel Pharmaceuticals quarterly return on equity?
The current quarterly ROE of CYCC is -2462.60%
What is the all time high quarterly ROE for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high quarterly return on equity is 250.90%
What is Cyclacel Pharmaceuticals quarterly ROE year-on-year change?
Over the past year, CYCC quarterly return on equity has changed by -2235.27% (-983.27%)